Otsuka has a proud history of developing and delivering medicines in the following therapeutic areas: central nervous system, nephrology and haematology. We have a number of approved products in Australia and New Zealand and many new treatments are being developed in areas such as haematology/oncology.
To view the Product Information (PI) and Consumer Medical Information (CMI) for each of our products, please click on the links below:
Approved products in Australia
Approved products in New Zealand
*Abilify Maintena® and Rexulti® are sponsored by Lundbeck Australia and co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Ltd.
Lundbeck Australia Pty Limited
1 Innovation Road
North Ryde NSW 2113
Ph: +61 2 8669 1000
Otsuka Australia Pharmaceutical Pty Limited
Suite 2.03, Level 2,
9 Help Street,
Chatswood NSW 2067
For further information about any of these products, please contact us.
Products: ABILIFY® (maintena), Abilify® (aripiprazole), Busulfex® (busulfan)Jinarc® (tolvaptan), Pletal® (cilostazol), Samsca® (tolvaptan), REXULTI® (brexpiprazole)